Results 141 to 150 of about 13,497 (214)

Positive inotropic effects of glucose-dependent insulinotropic polypeptide in the human atrium and the mouse atrium. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Neumann J, Hofmann B, Gergs U.
europepmc   +1 more source

Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity. [PDF]

J Med Chem
Wu B, Falsey JR, Netirojjanakul C, Herberich B, Holder JR, Sham K, Aral J, Forsythe N, Walker KW, Lu SC, Hager T, Stanislaus S, Komorowski R, Atangan L, Achmatowicz M, Romanini D, Weeraratne D, Miranda LP, Véniant MM, Cheng Y.   +19 more
europepmc   +1 more source

Dual-Targeted Glucose-Dependent Insulinotropic Polypeptide-Loaded Photothermal Nanoparticles to Prevent Obesity via Lipolysis and Browning of White Adipose Tissue. [PDF]

Small Sci
Xie T, Zhao L, Pei S, Wen K, Fei S, Chen W, Li Z, Zhang L, Li L, Guo L, Huang H, Pan Q.   +11 more
europepmc   +1 more source

Decoding the impact of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist on cardiometabolic health: inflammatory mediators at the focus. [PDF]

Diabetol Metab Syndr
Cheng F, Niu X, Wang Y, Yang F, Yang K, Li W.   +5 more
europepmc   +1 more source

Comparison of Perioperative Glycemic Control in Patients Continuing Versus Temporarily Holding Glucagon-Like Peptide-1 Receptor Agonists or Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists Preoperatively. [PDF]

AACE Endocrinol Diabetes
Trykall CC, Hill SB, James AM, Bagnola AJ, Wyne KL, Handley D, Brower KI.   +6 more
europepmc   +1 more source

The physiological impact of an N-terminal Halo-tag on glucose-dependent insulinotropic polypeptide receptor function in mice. [PDF]

Diabetes Obes Metab
Davies I, Manchanda Y, Sloop KW, Bloom SR, Tan TM, Tomas A, Jones B.   +6 more
europepmc   +1 more source

Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight. [PDF]

Mol Metab
Feetham CH, Ai M, Culotta I, Costa A, Hunter J, Brown RA, Coskun T, Emmerson PJ, D'Agostino G, Luckman SM.   +9 more
europepmc   +1 more source

Novel Use of Glucagon-Like Peptide-1 (GLP-1) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists in Maturity-Onset Diabetes of the Young (MODY). [PDF]

Cureus
Hilal A, Afandi B, Almazrouei R.
europepmc   +1 more source

Dysfunctional Lipid-Induced Secretion of Glucagon-Like Peptide-2(GLP-2), but Not of Incretins Glucagon-Like Peptide-1(GLP-1)/Glucose-Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia. [PDF]

MedComm (2020)
Musso G, Pinach S, Mella A, De Michieli F, Calabrese A, Trifiro D, Petrangolini G, Cassader M, Mariano F, Gambino R.   +9 more
europepmc   +1 more source

Molecular mechanisms underlying glucose-dependent insulinotropic polypeptide secretion in human duodenal organoids. [PDF]

Diabetologia
Guccio N, Alcaino C, Miedzybrodzka EL, Santos-Hernández M, Smith CA, Davison A, Bany Bakar R, Kay RG, Reimann F, Gribble FM.   +9 more
europepmc   +1 more source